11 completed, 3 terminated. 9 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 6, Terminated 3 |
| Phase 1 | 5 | Completed 5 |
Follow ABT-126: new trials by email Literature Review of ABT-126 trials Research Report on ABT-126
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680) ABT-126 - Schizophrenia | Phase 2 | Terminated | AbbVie | 268 | 2013-03-01 | 2018-05-02 |
| Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease ABT-126 - Alzheimer's Disease | Phase 2 | Terminated | AbbVie (prior sponsor, Abbott) | 343 | 2012-09-01 | 2021-08-02 |
| A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia ABT-126, Placebo - Schizophrenia | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 157 | 2012-08-01 | 2021-07-07 |
| This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease ABT-126 - Alzheimer's Disease | Phase 2 | Terminated | AbbVie (prior sponsor, Abbott) | 349 | 2012-08-01 | 2021-08-02 |
| A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia ABT-126, Placebo - Schizophrenia | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 432 | 2012-05-01 | 2021-07-07 |
| Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors ABT-126, placebo - Alzheimer's Disease | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 434 | 2012-03-01 | 2014-10-31 |
| Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease placebo, donepezil, ABT-126 - Alzheimer's Disease | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 438 | 2012-02-01 | 2014-11-19 |
| A Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease ABT-126, Placebo - Alzheimer's Disease | Phase 1 | Completed | Abbott | 20 | 2011-11-01 | 2012-05-02 |
| Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizophrenia ABT-126, Placebo - Cognitive Deficits in Schizophrenia | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 207 | 2010-03-01 | 2018-06-06 |
| Pharmacokinetic Study of ABT-126 in Stable Subjects With Schizophrenia ABT-126, Placebo for ABT-126 - Schizophrenia | Phase 1 | Completed | Abbott | 16 | 2009-11-01 | 2010-11-02 |
| Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease Placebo, ABT-126, donepezil - Alzheimer's Disease | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 274 | 2009-10-01 | 2013-01-31 |
| Pharmacokinetic Study of ABT-126 in Healthy Volunteers ABT-126, Placebo - Healthy Volunteers | Phase 1 | Completed | Abbott | 20 | 2009-08-01 | 2010-11-03 |
| Pharmacokinetic and Exploratory Biomarker Study of ABT-126 in Healthy Volunteers ABT-126, Placebo - Healthy | Phase 1 | Completed | Abbott | 10 | 2009-06-01 | 2010-11-02 |
| A Safety and Tolerability Study of ABT-126 in Elderly ABT-126 - Alzheimer's Disease | Phase 1 | Completed | Abbott | 30 | 2009-03-01 | 2010-11-02 |
Alzheimer Disease (7) · Schizophrenia (4)
AbbVie (prior sponsor, Abbott) (8) · Abbott (5) · AbbVie (1)
United States (14) · United Kingdom (7) · South Africa (5) · Russia (4) · Canada (2) · France (2) · Germany (2) · Greece (2) · Poland (2) · Ukraine (2) · Bulgaria (1) · Czechia (1) · Slovakia (1)
Laura Gault, MD (5) · George Haig, PharmD (4) · Hana Florian, MD (1)
PMID 28433500, PMID 26967214, PMID 27319970, PMID 27756421, PMID 28223265, PMID 28922590, PMID 29854928
2009 (1)